Novel Orexin 2 Receptor Agonist Shows Promise for Management of Narcolepsy and Idiopathic Hypersomnia
Results from a phase 1b trial demonstrate promise for a novel treatment developed to address the needs of patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock …